[Therapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Uganda]

Hdl Handle:
http://hdl.handle.net/10144/23218
Title:
[Therapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Uganda]
Authors:
Legros, D; Fournier, C; Gastellu-Etchegorry, M; Maiso, F; Szumilin, E
Journal:
Bulletin de la Société de Pathologie Exotique (1990)
Abstract:
The failure rate of melarsoprol after treatment of late stage cases of Human African Trypanosomiasis (HAT) is usually under 7%, even though the drug has been used for such treatment over the past 50 years. We report a melarsoprol treatment failure rate of 26.9% among 428 patients treated in Northern Uganda. Whatever its origin, this observation, the first documented in a HAT focus, is alarming, particularly since no second line trypanocidal drug is actually available for the treatment of late stage HAT. We believe that the current worrisome situation of HAT in several African countries and the risk of emergence of other foci of resistance, argue in favour of a greater attention on the part of the scientific community and the pharmaceutical companies being paid to this problem.
Affiliation:
Epicentre, Kampala, Ouganda. epi@imul.com
Issue Date:
Jul-1999
URI:
http://hdl.handle.net/10144/23218
PubMed ID:
10472443
Language:
fr
ISSN:
0037-9085
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorLegros, D-
dc.contributor.authorFournier, C-
dc.contributor.authorGastellu-Etchegorry, M-
dc.contributor.authorMaiso, F-
dc.contributor.authorSzumilin, E-
dc.date.accessioned2008-04-14T11:18:43Z-
dc.date.available2008-04-14T11:18:43Z-
dc.date.issued1999-07-
dc.identifier.citation[Therapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Uganda] 1999, 92 (3):171-2notBull Soc Pathol Exoen
dc.identifier.issn0037-9085-
dc.identifier.pmid10472443-
dc.identifier.urihttp://hdl.handle.net/10144/23218-
dc.description.abstractThe failure rate of melarsoprol after treatment of late stage cases of Human African Trypanosomiasis (HAT) is usually under 7%, even though the drug has been used for such treatment over the past 50 years. We report a melarsoprol treatment failure rate of 26.9% among 428 patients treated in Northern Uganda. Whatever its origin, this observation, the first documented in a HAT focus, is alarming, particularly since no second line trypanocidal drug is actually available for the treatment of late stage HAT. We believe that the current worrisome situation of HAT in several African countries and the risk of emergence of other foci of resistance, argue in favour of a greater attention on the part of the scientific community and the pharmaceutical companies being paid to this problem.en
dc.languagefre-
dc.language.isofren
dc.rightsArchived with thanks to Bulletin de la Société de Pathologie Exotique (1990)en
dc.subject.meshDrug Resistanceen
dc.subject.meshHumansen
dc.subject.meshMelarsoprolen
dc.subject.meshTreatment Failureen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosomiasis, Africanen
dc.subject.meshUgandaen
dc.title[Therapeutic Failure of Melarsoprol Among Patients Treated for Late Stage T.b. Gambiense Human African Trypanosomiasis in Uganda]fr
dc.contributor.departmentEpicentre, Kampala, Ouganda. epi@imul.comen
dc.identifier.journalBulletin de la Société de Pathologie Exotique (1990)en

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.